Transition from epoprostenol to treprostinil in pulmonary arterial hypertension: a controlled trial

被引：0
|
作者：
Schilz, R.
Rubenfire, M.
Mclaughlin, V.
Allen, R.
Elliott, G.
Park, M.
Wade, M.
机构：
[1] Case Western Reserve Univ Hosp, Cleveland, OH 44106 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA
[4] LDS Hosp, Salt Lake City, UT USA
[5] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[6] United Therapeut Corp, Res Triangle Pk, NC USA
来源：
EUROPEAN HEART JOURNAL | 2006年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：622 / 622
页数：1
相关论文
共 50 条
  • [1] Transition from epoprostenol to treprostinil in pulmonary arterial hypertension: A controlled trial
    Rubenfire, Melvyn
    McLaughlin, Vallerie
    Allen, Roblee
    Elliott, Gregory
    Park, Myung
    Wade, Michael
    Schilz, Robert J.
    CHEST, 2006, 130 (04) : 258S - 258S
  • [2] Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: A controlled trial
    Rubenfire, Melvyn
    McLaughlin, Vallerle V.
    Allen, Roblee P.
    Elliott, Greg
    Park, Myung H.
    Wade, Michael
    Schilz, Robert
    CHEST, 2007, 132 (03) : 757 - 763
  • [3] Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension
    Reisbig, KA
    Coffman, PA
    Floreani, AA
    Bultsma, CJ
    Olsen, KM
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (04) : 739 - 743
  • [4] Transition from IV Epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: A controlled trial (vol 132, pg 757, 2007)
    Rubenfire
    CHEST, 2007, 132 (05) : 1721 - 1721
  • [5] Multicenter experience with the rapid transition to intravenous treprostinil from epoprostenol in pulmonary arterial hypertension
    Shapiro, Shelley
    Waxman, Aaron
    Schilz, Robert
    Strootman, Deb
    Rollins, Kristan
    Feldman, B. Jeremy
    CHEST, 2007, 132 (04) : 635S - 635S
  • [6] Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension
    Gomberg-Maitland, M
    Tapson, VF
    Benza, RL
    McLaughlin, VV
    Krichman, A
    Widlitz, AC
    Barst, RJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (12) : 1586 - 1589
  • [7] Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension
    Sarangarm, Preeyaporn
    Elwood, Kirsten
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (23) : 2110 - 2115
  • [8] Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil
    Ivy, D. Dunbar
    Claussen, Lori
    Doran, Aimee
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (05): : 696 - 698
  • [9] Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension
    Mouratoglou, Sophia Anastasia
    Patsiala, Anthoula
    Feloukidis, Christos
    Karvounis, Haralambos
    Giannakoulas, George
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 187 - 189
  • [10] Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension
    Vachiéry, JL
    Hill, N
    Zwicke, D
    Barst, R
    Blackburn, S
    Naeije, R
    CHEST, 2002, 121 (05) : 1561 - 1565
12345